About LivaNova
LivaNova is a company based in London (United Kingdom) founded in 2015. The company has 2,900 employees as of December 31, 2024. LivaNova has completed 4 acquisitions, including ALung, Caisson International and ImThera Medical. LivaNova offers products and services including Essenz™ Perfusion System, VNS Therapy™ for Epilepsy, and VNS Therapy™ for Depression.
- Headquarter London, United Kingdom
- Employees 2900 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Livanova Plc
-
Annual Revenue
$1.25 B (USD)8.66as on Dec 31, 2024
-
Net Profit
$63.23 M (USD)260.39as on Dec 31, 2024
-
EBITDA
$216.58 M (USD)35.53as on Dec 31, 2024
-
Latest Funding Round
$1.23 M (USD), Grant
Jan 01, 2021
-
Investors
European Union
& 1 more
-
Employee Count
2900
as on Dec 31, 2024
-
Investments & Acquisitions
ALung
& 3 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of LivaNova
LivaNova is a publicly listed company on the NASDAQ with ticker symbol LIVN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of LivaNova
LivaNova offers a comprehensive portfolio of products and services, including Essenz™ Perfusion System, VNS Therapy™ for Epilepsy, and VNS Therapy™ for Depression.
System for supporting cardiopulmonary functions during procedures.
Device that treats drug-resistant epilepsy through nerve stimulation.
Device aimed at managing difficult-to-treat depression via stimulation.
People of LivaNova
Unlock access to complete
Unlock access to complete
Software Development Team
61 people
Leadership Team
27 people
Finance and Accounting
25 people
Human Resources and Administration
23 people
Operations Team
15 people
Data Analysis and Operations Team
12 people
Sales and Marketing
10 people
Legal and Compliance
8 people
Unlock access to complete
Funding Insights of LivaNova
Investors in LivaNova
LivaNova has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include European Union and Ministry of Economic Development & Trade.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
Timely advice is provided to foreign investors on economic opportunities.
|
Locked | Locked | Locked |
Investor details for LivaNova
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by LivaNova
LivaNova has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include ALung, Caisson International and ImThera Medical.
Investment portfolio details for LivaNova
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Implantable neurostimulation devices for obstructive sleep apnea are developed.
|
Locked | Locked | 2008 | Locked | |
|
Extracorporeal CO2 removal systems are developed to supplement mechanical ventilation.
|
Locked | Locked | 1997 | Locked | |
|
Circulatory support devices and ventricular assist systems are provided.
|
Locked | Locked | 1996 | Locked |
Complete acquisition details for LivaNova
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - LivaNova
Detailed financials for LivaNova
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Livanova Comparisons
Peer comparison for LivaNova
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of LivaNova
Detailed competitors of LivaNova
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Livanova
Complete news archive for LivaNova
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about LivaNova
LivaNova was founded in 2015.
LivaNova is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
As of Dec 31, 2024, the latest employee count at LivaNova is 2,900.
Annual revenue of LivaNova is $1.25B as on Dec 31, 2024.
LivaNova was founded in 2015 and is headquartered in London, United Kingdom. Operations focus on the medical device sector, where cardiac rhythm management and neuromodulation products are developed and distributed. Services include advanced surgical tools and monitoring systems for heart and brain therapies. Global reach is maintained through regulatory compliance and partnerships in healthcare markets, supporting clinical applications across various regions.
LivaNova offers Essenz™ Perfusion System, VNS Therapy™ for Epilepsy, and VNS Therapy™ for Depression.
Yes, LivaNova is publicly traded on NASDAQ under the ticker symbol LIVN.
LivaNova has made 4 acquisitions, including ALung, Caisson International, and ImThera Medical.
LivaNova has 2 investors. Key investors include European Union, and Ministry of Economic Development & Trade.
The ticker symbol of LivaNova is LIVN on NASDAQ.